Faculty Profiles - HIRASAWA Akira

Papers - HIRASAWA Akira

Division display 101 - 120 of about 403 ／ All the affair displays >>

がんゲノム医療と女性ヘルスケア Reviewed

HIRASAWA AKIRA

医学のあゆみ 269 ( 1 ) 85 - 88 2019.4

婦人科がんとがんゲノム医療 Reviewed

HIRASAWA AKIRA

Pharma Medica 37 ( 2 ) 9 - 14 2019.2

婦人科における遺伝性腫瘍 Reviewed

HIRASAWA AKIRA

産婦人科の実際 68 ( 2 ) 187 - 191 2019.2

Sentinel Node Navigation Surgery for Endometrial Cancer

Susumu Nobuyuki, Yamagami Wataru, Kataoka Fumio, Hirano Takuro, Makabe Takeshi, Sakai Kensuke, Chiyoda Tatsuyuki, Nomura Hiroyuki, Hirasawa Akira, Aoki Daisuke

SURGERY FOR GYNECOLOGIC CANCER 295 - 312 2019

Genome-wide DNA methylation profile of young-onset endometrial cancer

Makabe Takeshi, Arai Eri, Hirasawa Akira, Yamagami Wataru, Susumu Nobuyuki, Aoki Daisuke, Kanai Yae

CANCER SCIENCE 109 1304 - 1304 2018.12

遺伝性乳癌卵巣癌に対するリスク低減卵管卵巣摘出後のQOLに関する検討 Reviewed

谷本慧子, 平沢晃, 牧田和也, 岩田卓, 堀場裕子, 横田めぐみ, 小川真里子, 弟子丸亮太, 柳本茂久, 高松潔, 青木大輔

日本女性医学学会雑誌 26 ( 1 ) 45 - 47 2018.11

Synchronous endometrial and ovarian cancer in Lynch syndrome with a MSH2 germline mutation: A case report. Reviewed International journal

Takashi Takeda, Kouji Banno, Megumi Yanokura, Mayuka Anko, Arata Kobayashi, Asako Sera, Takayuki Takahashi, Masataka Adachi, Yusuke Kobayashi, Shigenori Hayashi, Hiroyuki Nomura, Akira Hirasawa, Eiichiro Tominaga, Daisuke Aoki

Molecular and clinical oncology 9 ( 5 ) 479 - 484 2018.11

Language：English Publishing type：Research paper (scientific journal)

Synchronous endometrial and ovarian cancer (SEOC) is a rare entity among gynecological cancers, which exhibits endometrioid histology in its early stages and generally has a good prognosis. However, diagnosis is difficult and recent reports have demonstrated that most clinically diagnosed cases of SEOC have clonally related cancers, indicating metastatic cancer. The association of SEOC with Lynch syndrome is also not clearly understood. We herein present the case of a 41-year-old SEOC patient with MSH2 mutation. The endometrial cancer was an endometrioid adenocarcinoma and the ovarian cancer was mainly endometrioid, but also included a clear cell carcinoma with a borderline clear cell adenofibromatous component, indicating primary ovarian cancer. Both tumors exhibited microsatellite instability (MSI) and loss of expression of MSH2 and MSH6. The patient had a family history of colorectal and gastric cancers. Genetic analysis revealed a germline mutation in exon 6 of MSH2 (c.1042C>T, p.Gln348*) and the patient was diagnosed with Lynch syndrome. This MSH2 mutation has only been registered in one case in the InSiGHT variant databases and has not been reported in a gynecological tumor or SEOC to date. This case is a rare example of a patient with genetically diagnosed Lynch syndrome who also developed SEOC. This synchronous cancer is not common, but it may be caused by Lynch syndrome. Testing for MSI and immunohistochemistry for mismatch repair deficiency is necessary in cases with suspected SEOC.

DOI： 10.3892/mco.2018.1723

PubMed

researchmap

遺伝性腫瘍・家族性腫瘍

HIRASAWA AKIRA

日本医師会雑誌 147 ( 7 ) 1401 - 1406 2018.10

GENOME-WIDE DNA METHYLATION ANALYSIS IN YOUNG-ONSET ENDOMETRIAL CANCER

Makabe T, Arai E, Hirasawa A, Yamagami W, Nobuyuki S, Aoki D, Kanai Y

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 28 79 - 79 2018.9

THE EFFICACY OF REPEATED HORMONAL THERAPY FOR INTRAUTERINE RECURRENCE FOLLOWING FERTILITY PRESERVING HORMONAL THERAPY FOR ENDOMETRIAL CANCER OR ATYPICAL ENDOMETRIAL HYPERPLASIA. Reviewed

Hirano T, Yamagami W, Susumu N, Makabe T, Sakai K, Ninomiya T, Chiyoda T, Nomura H, Kataoka F, Hirasawa A, Banno K, Aoki D

INTERNATIONAL JOURNAL OF GYNECOLOGIC CANCER 28 ( S2 ) 1092 - 1092 2018.9

UNSUCCESSFUL HIGH-DOSE HORMONAL THERAPY FOR ENDOMETRIAL CANCER OR ATYPICAL ENDOMETRIAL HYPERPLASIA. Reviewed

Tamagawa M, Yamagami W, Hirano T, Makabe T, Sakai K, Ninomiya T, Chiyoda T, Nomura H, Kataoka F, Hirasawa A, Banno K, Susumu N, Aoki D

INTERNATIONAL JOURNAL OF GYNECOLOGIC CANCER 28 ( S2 ) 1189 - 1189 2018.9

がんゲノム医療とHBOC

HIRASAWA AKIRA

日本HBOCコンソーシアムニュースレター 6 2018.9

婦人科疾患ゲノム異常の探索と女性ヘルスケアの個別化

HIRASAWA AKIRA

101 64 - 67 2018.8

GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes. Reviewed International journal

Yoshihama T, Fukunaga K, Hirasawa A, Nomura H, Akahane T, Kataoka F, Yamagami W, Aoki D, Mushiroda T

Oncotarget 9 ( 51 ) 29789 - 29800 2018.7

Language：English Publishing type：Research paper (scientific journal)

Purpose: To find genetic variants that predicted toxicity and/or efficacy of paclitaxel plus carboplatin combination therapy (TC therapy). Patients and methods: In a retrospective case-control study, we analyzed 320 patients who had received TC therapy for gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, and cervical cancers) and collected their germline DNA. We performed a comprehensive pharmacogenomic analysis using a targeted resequencing panel of 100 pharmacogenes. For 1,013 variants passing QC, case-control association studies and survival analyses were conducted. Results: GSTP1 rs1695 showed the smallest p value for hematotoxicity association, and the 105Ile wild type allele had a significantly higher risk of severe hematotoxicity (neutropenia G4, thrombocytopenia ≥ G3 and anemia ≥ G3) than the 105Val allele (p=0.00034, odds ratio=5.71 (95% confidence interval:1.77-18.44)). Next, we assessed 5-year progression-free survival (PFS) and overall survival (OS) in 56 advanced ovarian cancer patients who received tri-weekly TC as a first-line chemotherapy. Patients with the 105Ile/105Ile genotype showed significantly better PFS (p=0.00070) and OS (p=0.0012) than those with the 105Ile/105Val or 105Val/105Val genotype. Conclusion: Our study indicates that the GSTP1 rs1695 105Ile/105Ile genotype is associated with both severe hematotoxicity and high efficacy of TC therapy, identifying a possible prognostic indicator for patients with TC therapy.

DOI： 10.18632/oncotarget.25712

PubMed

researchmap

有害事象によりベバシズマブ投与を中止した婦人科がん症例の検討 Reviewed

大野あゆみ, 千代田達幸, 野村弘行, 同前愛, 早乙女啓子, 冨永英一郎, 岩田卓, 山上亘, 片岡史夫, 平沢晃, 田中守, 青木大輔

東京産科婦人科学会会誌 67 ( 3 ) 396 - 400 2018.7

遺伝性腫瘍に対するリスク低減卵管卵巣摘出術－RRSOの臨床試験やその適応、手技の実際と留意すべきポイント－

AOKI DAISUKE

産婦人科の実際 67 ( 5 ) 549 - 556 2018.5

遺伝性乳がん

AOKI DAISUKE

White 6 ( 1 ) 15 - 22 2018.5

遺伝性乳癌卵巣癌症候群に対するリスク低減卵管卵巣摘出後の漢方療法に関する検討 Reviewed

平沢晃, 牧田和也, 岩田卓, 堀場裕子, 横田めぐみ, 小川真里子, 弟子丸亮太, 柳本茂久, 青木大輔

産婦人科漢方研究のあゆみ 35 ( 35 ) 189 - 191 2018.4

Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? Reviewed International journal

Wataru Yamagami, Nobuyuki Susumu, Takeshi Makabe, Kensuke Sakai, Hiroyuki Nomura, Fumio Kataoka, Akira Hirasawa, Kouji Banno, Daisuke Aoki

JOURNAL OF GYNECOLOGIC ONCOLOGY 29 ( 2 ) e21 2018.3

Language：English Publishing type：Research paper (scientific journal) Publisher：KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY

Objective: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking. We aimed to clarify the outcomes of repeated MPA therapy in cases of intrauterine recurrence after fertility-preserving therapy with MPA against AEH/early G1.Methods: Patients with AEH or stage IA well-differentiated endometrioid carcinoma without myometrial invasion who underwent first-line MPA therapy for primary lesions or intrauterine recurrence were divided into initial treatment and repeated treatment groups (162 and 82 patients, respectively). Oral MPA administration (400-600 mg/day) was continued until pathological tumor disappearance. Data regarding clinicopathological factors, adverse events, and outcomes following the initial and repeated hormonal treatments were extracted from medical records and analyzed.Results: Complete response rates in the initial and repeated treatment groups were 98.5% and 96.4%, respectively, among patients with AEH, and were 90.7% and 98.1%, respectively, among patients with G1. In the initial treatment group, 5-year recurrence-free survival (RFS) rates were 53.7% and 33.2% among patients with AEH and G1, respectively. In the repeated treatment group, RFS rates were 14.0% and 11.2% among patients with AEH and G1, respectively. Among patients with AEH, the pregnancy rate tended to be lower in the repeated treatment group than in the initial treatment group (11.1% vs. 29.2%; p=0.107), while no significant group difference was observed among patients with G1 (20.8% vs. 22.7%).Conclusion: Repeated treatment is sufficiently effective for intrauterine recurrence after hormonal therapy for AEH/early G1.

DOI： 10.3802/jgo.2018.29.e21

婦人科疾患ゲノム異常の探索と女性ヘルスケアの個別化 Invited Reviewed

HIRASAWA AKIRA

日本女性医学学会雑誌 25 ( 2 ) 156 - 158 2018.2

　 PREV - NEXT 　

< HIRASAWA Akira >

Papers - HIRASAWA Akira